2022 年第 3 期 第 17 卷

恩格列净联合吡格列酮二甲双胍治疗2型糖尿病的临床效果

Clinical effect on empagliflozin combined with pioglitazone hydrochlorid and metformin hydrochlorid on type 2 diabetes mellitus

作者：阮丹丹1林勇2王寅1

英文作者：Ruan Dandan1 Lin Yong2 Wang Yin1

单位：1中国人民解放军联勤保障部队第九〇三医院药剂科，杭州310012；2杭州师范大学附属医院药剂科，杭州310000

英文单位：1Department of Pharmacy the 903rd Hospital of the Chinese People′s Liberation Army Joint Logistic Support Force Hangzhou 310012 China; 2Department of Pharmacy the Affiliated Hospital of Hangzhou Normal University Hangzhou 310000 China

关键词：2型糖尿病；恩格列净；吡格列酮二甲双胍

英文关键词：Type2diabetesmellitus;Empagliflozin;Pioglitazonehydrochlorideandmetforminhydrochloride

• 摘要：

• 目的 探讨恩格列净联合吡格列酮二甲双胍治疗2型糖尿病（T2DM）的临床效果。方法  收集2019年8月至2020年8月于中国人民解放军联勤保障部队第九〇三医院就诊的107例T2DM患者的临床资料进行回顾性分析。按治疗方法不同分为对照组（49例）和观察组（58例）。对照组给予吡格列酮二甲双胍治疗，观察组给予恩格列净联合吡格列酮二甲双胍治疗。比较2组治疗前后的血糖、体重指数、血脂及血压的变化情况，观察治疗期间的不良反应。结果 治疗后，2组空腹血糖、餐后2 h血糖、糖化血红蛋白、体重指数均低于治疗前，且观察组均低于对照组［（7.3±1.0）mmol/L比（8.5±1.4）mmol/L、（8.0±1.0）mmol/L比（9.7±1.0）mmol/L、（7.5±1.0）%比（8.4±0.8）%、（25.2±1.4）kg/m2比（26.8±1.4）kg/m2］，差异均有统计学意义（均P＜0.05）。治疗后观察组收缩压、舒张压、三酰甘油水平均低于治疗前且低于对照组，差异均有统计学意义（均P＜0.05）。治疗期间观察组不良反应发生率显著低于对照组［12.1%（7/58）比22.4%（11/49）］，差异有统计学意义（P＜0.05）。结论  恩格列净联合吡格列酮二甲双胍治疗T2DM效果显著，在降糖的同时，对体重指数和血压也具有一定下调作用。

• Objective   To explore the clinical effect of empagliflozin combined with pioglitazone hydrochlorid and metformin hydrochlorid on type 2 diabetes mellitus(T2DM). Methods   The clinical data of 107 patients with T2DM admitted to the 903rd Hospital of the Chinese People′s Liberation Army Joint Logistics Support Force from August 2019 to August 2020 were analyzed retrospectively. According to the different treatment regimens, the patients were divided into control group(49 cases) and observation group(58 cases). The control group was treated with pioglitazone hydrochlorid and metformin hydrochlorid, and the observation group was treated with empagliflozin combined with pioglitazone hydrochlorid and metformin hydrochlorid. The changes of blood glucose, body mass index, blood lipid and blood pressure before and after treatment were compared between the two groups, and the adverse reactions during treatment were observed. Results  After treatment, fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin and body mass index in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group［(7.3±1.0)mmol/L vs (8.5±1.4)mmol/L, (8.0±1.0)mmol/L vs (9.7±1.0)mmol/L, (7.5±1.0)% vs (8.4±0.8)%, (25.2±1.4)kg/m2 vs (26.8±1.4) kg/m2］(all P<0.05). After treatment, levels of systolic blood pressure, diastolic blood pressure and triacylglycerol in the observation group were lower than those before treatment and lower than those in the control group(all P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group［12.1%(7/58) vs 22.4%(11/49)］(P<0.05). Conclusions Empagliflozin combined with pioglitazone hydrochlorid and metformin hydrochlorid has significant effect on T2DM. While blood glucose lowering, it also can significantly reduce the patient′s body mass index and blood pressure.